Journal of Clinical Oncology, Vol 21, Issue 3
(February), 2003: 433-440
© 2003 American Society for Clinical Oncology
Impact of Diabetes Mellitus on Outcomes in Patients With Colon Cancer
Jeffrey A. Meyerhardt,
Paul J. Catalano,
Daniel G. Haller,
Robert J. Mayer,
John S. Macdonald,
Al B. Benson, III,
Charles S. Fuchs
From the Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; University of Pennsylvania Cancer Center, Philadelphia, PA; St. Vincent Clinical Cancer Center, New York, NY; Northwestern University, Division of Hematology-Oncology, Chicago, IL
Address reprint requests to Jeffrey Meyerhardt, MD, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115; email: jmeyerhardt{at}partners.org.
Purpose: To determine the influence of diabetes mellitus on long-term outcomes and treatment-related toxicity among patients with curatively resected colon cancer.
Patients and Methods: This study was a cohort study within a large, randomized adjuvant chemotherapy trial of 3,759 patients with high-risk stage II and stage III colon cancer treated between 1988 and 1992 throughout the United States. In the cohort, 287 patients were identified as having diabetes mellitus. With a median follow-up of 9.4 years, we analyzed differences in overall survival (OS) and colon cancer recurrence as well as treatment-related toxicity between patients with diabetes and those without diabetes.
Results: At 5 years, patients with diabetes mellitus, compared with patients without diabetes, experienced a significantly worse disease-free survival (DFS; 48% diabetics v 59% nondiabetics; P < .0001), OS (57% v 66%; P < .0001), and recurrence-free survival (RFS; 56% v 64%, P = .012). Median survival was 6.0 years and 11.3 years for diabetics and nondiabetics, respectively. Compared with patients without a history of diabetes, those with diabetes had a 42% increased risk of death from any cause (P < .0001) and 21% increased risk for recurrence (P = .05) after adjustment for other predictors of colon cancer outcome. Treatment-related toxicities were similar between the two groups, although patients with diabetes experienced an increase in treatment-related diarrhea.
Conclusion: Patients with diabetes mellitus and high-risk stage II and stage III colon cancer experienced a significantly higher rate of overall mortality and cancer recurrence, even after adjustment for other predictors of colon cancer outcome. These results underscore the need for further research to understand the mechanism that underlies this relation.
Dr. Meyerhardt is a trainee in the Program in Cancer Epidemiology, National Research Service Award T32 CA 090001-27.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
T. P. Srokowski, S. Fang, G. N. Hortobagyi, and S. H. Giordano
Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients With Breast Cancer
J. Clin. Oncol.,
May 1, 2009;
27(13):
2170 - 2176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Field, M. Croxford, I. Hastie, F. Chen, S. Kosmider, J. Desai, and P. Gibbs
Impact of Body Mass Index on Colorectal Cancer Treatment and Outcomes: Need for Prospective and Comprehensive Data
J. Clin. Oncol.,
March 20, 2009;
27(9):
1524 - 1526.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Derr, X. Ye, M. U. Islas, S. Desideri, C. D. Saudek, and S. A. Grossman
Association Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma
J. Clin. Oncol.,
March 1, 2009;
27(7):
1082 - 1086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Polednak
Recognition of comorbid diabetes and obesity in hospital records of newly diagnosed cancer patients
Ann. Onc.,
March 1, 2009;
20(3):
591 - 592.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. B. Barone, H.-C. Yeh, C. F. Snyder, K. S. Peairs, K. B. Stein, R. L. Derr, A. C. Wolff, and F. L. Brancati
Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus: A Systematic Review and Meta-analysis
JAMA,
December 17, 2008;
300(23):
2754 - 2764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Thompson, T. S. Church, I. Janssen, P. T. Katzmarzyk, C. P. Earnest, and S. N. Blair
Cardiorespiratory Fitness as a Predictor of Cancer Mortality Among Men With Pre-Diabetes and Diabetes
Diabetes Care,
April 1, 2008;
31(4):
764 - 769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Min Park, M. Kyung Lim, K. Won Jung, S. Ae Shin, K.-Y. Yoo, Y. Ho Yun, and B. Yul Huh
Prediagnosis Smoking, Obesity, Insulin Resistance, and Second Primary Cancer Risk in Male Cancer Survivors: National Health Insurance Corporation Study
J. Clin. Oncol.,
October 20, 2007;
25(30):
4835 - 4843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Extermann and A. Hurria
Comprehensive Geriatric Assessment for Older Patients With Cancer
J. Clin. Oncol.,
May 10, 2007;
25(14):
1824 - 1831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Park, M. K. Lim, S. A. Shin, and Y. H. Yun
Impact of Prediagnosis Smoking, Alcohol, Obesity, and Insulin Resistance on Survival in Male Cancer Patients: National Health Insurance Corporation Study
J. Clin. Oncol.,
November 1, 2006;
24(31):
5017 - 5024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. T. Bloomgarden
Third Annual World Congress on the Insulin Resistance Syndrome: Associated conditions.
Diabetes Care,
September 1, 2006;
29(9):
2165 - 2174.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Goldberg, D. Niedzwiecki, M. Bertagnolli, A. W. Blackstock, J. E. Tepper, and R. J. Mayer
Cancer and leukemia group B gastrointestinal cancer committee.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3589s - 3595s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Haller, P. J. Catalano, J. S. Macdonald, M. A. O'Rourke, M. S. Frontiera, D. V. Jackson, and R. J. Mayer
Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089
J. Clin. Oncol.,
December 1, 2005;
23(34):
8671 - 8678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Geraci, C. P. Escalante, J. L. Freeman, and J. S. Goodwin
Comorbid Disease and Cancer: The Need for More Relevant Conceptual Models in Health Services Research
J. Clin. Oncol.,
October 20, 2005;
23(30):
7399 - 7404.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. O. Keku, P. K. Lund, J. Galanko, J. G. Simmons, J. T. Woosley, and R. S. Sandler
Insulin Resistance, Apoptosis, and Colorectal Adenoma Risk
Cancer Epidemiol. Biomarkers Prev.,
September 1, 2005;
14(9):
2076 - 2081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sastre, E. Marcuello, B. Masutti, M. Navarro, S. Gil, A. Anton, A. Abad, E. Aranda, J. Maurel, M. Valladares, et al.
Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
J. Clin. Oncol.,
May 20, 2005;
23(15):
3545 - 3551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G Renehan and S. M Shalet
Diabetes, insulin therapy, and colorectal cancer
BMJ,
March 12, 2005;
330(7491):
551 - 552.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Boyd
Insulin and Cancer
Integr Cancer Ther,
December 1, 2003;
2(4):
315 - 329.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Meyerhardt, P. J. Catalano, D. Schrag, J. Z. Ayanian, D. G. Haller, R. J. Mayer, J. S. Macdonald, A. B. Benson III, and C. S. Fuchs
Association of Hospital Procedure Volume and Outcomes in Patients with Colon Cancer at High Risk for Recurrence
Ann Intern Med,
October 21, 2003;
139(8):
649 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
